Navigation Links
Keryx Biopharmaceuticals' Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
Date:9/14/2009

tients with end-stage renal disease, and Keryx is in the process of finalizing the U.S. Phase 3 program for Zerenex in consultation with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for KRX-0401, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete clinical trials for KRX-0401; our ability to meet anticipated development timelines for KRX-0401 due to recruitment, clinical trial results, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available athttp://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

    KERYX CONTACT:
        Lauren Fischer
        Director, Investor Relations
        Keryx Biopharmaceuticals, Inc.
        Tel: 212.531.5962
        E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... , May 6, 2015  Mirati Therapeutics, Inc. ("Mirati") ... the first quarter ended March 31, 2015 and provided ... "We continue to make progress across our targeted ... M.D., Ph.D., president and CEO, Mirati. "We look forward ... American Society of Clinical Oncology meeting at the end ...
(Date:5/6/2015)... 2015 Delcath Systems, Inc. (NASDAQ: DCTH ... on oncology with an emphasis on the treatment of ... the three months ended March 31, 2015.  ... include: , Achieved quarterly product revenue of $0.44 ... the first quarter of 2014; , Activated a ...
(Date:5/6/2015)... and influencers across North America have ... melanoma prevention begins with parents-encouraging everyone to create a #newfamilyrule ... , and parenting author Alyson Schafer are among ... to share this poignant video message: Click ... Melanoma Fund (DCMF)-producers of the viral video Dear ...
Breaking Medicine Technology:Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update 2Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update 3Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update 4Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update 5Delcath Reports 2015 First Quarter Financial Results 2Delcath Reports 2015 First Quarter Financial Results 3Delcath Reports 2015 First Quarter Financial Results 4Delcath Reports 2015 First Quarter Financial Results 5Delcath Reports 2015 First Quarter Financial Results 6Delcath Reports 2015 First Quarter Financial Results 7Delcath Reports 2015 First Quarter Financial Results 8Celebrities Tweet Their Support of Melanoma Awareness Month and #newfamilyrule 2
... NEWPORT NEWS, Va . , April 30 A ... in Las Vegas , found that Breast-Specific Gamma Imaging (BSGI) is ...   , , , ... breast imaging technique (MBI), has been proven in several other studies to ...
... HAMILTON, Bermuda , April 30 Celtic Pharmaceutical Holdings ... and pharmaceutical industries, announced today the enrolment of the first patient into ... topical treatment of onychomycosis (also known as a fungal nail infection).   ... This Phase III trial ...
Cached Medicine Technology:BSGI Offers Clear View of Breast Tumor Response to Neoadjuvant Chemotherapy 2Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis 2Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis 3Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis 4
(Date:5/6/2015)... Texas (PRWEB) May 06, 2015 ... of the HIMSS EMR Adoption Model, the hospital ... improve patient engagement and automate processes. The leadership ... from paper-driven to electronic workflows, patient registration still ... copies of consents. With HIMSS Stage 7 attestation ...
(Date:5/6/2015)... A quality built chicken coop condo with a wheel kit ... raise chickens on a pasture. By installing a wheel kit ... a chicken tractor that stands up to being moved around the ... is able to flex to uneven ground without losing its shape. ... fertilized, and it will help provide the chickens with fresh foraging ...
(Date:5/6/2015)... Experienced Vancouver air conditioning installation and ... they will now conduct their cooling services, including air ... to commercial and residential units. Strata complex air conditioning ... of technical knowledge as well as a professionally trained ... will take away any old air conditioning unit to ...
(Date:5/6/2015)... May 06, 2015 Chesapeake Regional ... state of Virginia to acquire Intuitive Surgical, Inc.’s ... The system upgrade includes enhanced surgical technique capabilities, ... procedures across a wide spectrum of specialties. Its ... pain and quicker recovery times. , “As the ...
(Date:5/6/2015)... North Vancouver, BC (PRWEB) May 06, 2015 ... leading colon hydrotherapy supplier, is excited to announce ... which will help reduce the industry’s carbon footprint ... These kits feature Eco-Flex™, the ... hydrotherapy. “This is a game-changer for hydrotherapists,” claims ...
Breaking Medicine News(10 mins):Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 2Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 3Health News:Chicken Coop Condo Launches the Chicken Tractor 2Health News:Pro Ace Care Now Does Air Conditioning Installation for Strata Complexes 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 3Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 2Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 3
... Highlights:, - Revenue of $174 million, up 187% from same ... Providence base social services segment grew 29%, - Net income ... of $1.6 million, attributable to management bonuses and $350,000 ... $0.09 per diluted share - Cash flow of ...
... the evolution of its pioneering stem cell program, the ... million grant from the California Institute for Regenerative Medicine ... building on its campus. , The $119 million building, ... approved by the UC Regents in March, contingent on ...
... ALEXANDRIA, Va., May 7 The American ... physician,assistants (PAs) practicing in the U.S., is ... the Public Health Service-sponsored guidelines,on Treating Tobacco ... updated tobacco cessation guidelines provide even stronger,evidence ...
... May 7 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals,a developer and ... today announced the appointment of David B. Holtz ... 8, 2008. In these,roles, Mr. Holtz will be ... Management and Information Technology reporting to,Thomas E. Gardner, ...
... is common in the aggressive form of the disease, ... For the first time, a gene linked to the ... report. , "This is the first paper that helps ... researcher Dr. John M. Maris, director of the Center ...
... May 7 Derma Sciences, Inc.,(OTC Bullentin Board: DSCI), ... its first quarter 2008 results before market on,Thursday, May ... that same,day to discuss the results at 11:00 am ... 617 213 8846 (international), with passcode,26916332 to access the ...
Cached Medicine News:Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 2Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 3Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 4Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 5Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 6Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 7Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 8Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 9Health News:Providence Service Corporation Announces 187% Revenue Increase in First Quarter of 2008 10Health News:UCSF receives funding for building from California stem cell agency 2Health News:UCSF receives funding for building from California stem cell agency 3Health News:AAPA Endorses 2008 Public Health Service Guidelines for Treating Tobacco Use and Dependence 2Health News:NUCRYST Appoints David B. Holtz as Vice President and Chief Financial Officer 2Health News:NUCRYST Appoints David B. Holtz as Vice President and Chief Financial Officer 3Health News:NUCRYST Appoints David B. Holtz as Vice President and Chief Financial Officer 4Health News:Gene Variation Linked to Neuroblastoma, a Childhood Cancer 2Health News:Gene Variation Linked to Neuroblastoma, a Childhood Cancer 3Health News:Derma Sciences Announces Date of Its First Quarter 2008 Earnings Release and Conference Call on May 15, 2008 2
An enzyme linked immunosorbent assay (ELISA) for the detection and quantitationof RF IgG isotype in human serum of patients with rheumatoid arthritis....
An enzyme linked immunosorbant assay (ELISA) for the detection and quantitation of Rheumatoid Factor (RF) of IgM isotype in human serum....
An enzyme linked immunoassay (ELISA) for the detection and semiquantitationof IgG and IgM antibodies to 2-GP1, as an aid in assessingthe risk of thrombosis in patients with Systemic Lupus Erythematos...
An enzyme linked immunoassay (ELISA) for the detection and semiquantitation of IgG, IgA or IgM anticardiolipin antibodies, as an aid in assessing the risk of thrombosis in individuals with Systemic L...
Medicine Products: